The discovery of dabigatran etexilate for the treatment of venous thrombosis
Authors:
- 9 May 2016
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 11 (7) , 717-731
Abstract
Introduction: Venous thromboembolism (VTE) can be life-threatening and requires anticoagulant treatment; for many years, vitamin K antagonists, e.g. warfarin, were the only oral anticoagulants available for long-term treatment. Although highly effective, they have many limitations including a slow onset, a multitude of drug–drug and drug–food interactions, and a narrow therapeutic range. These limitations spurred the search for non-vitamin K antagonist oral anticoagulants (NOACs), such as dabigatran etexilate. Areas covered: The authors illustrate the progression of preclinical and clinical studies leading to the development of dabigatran, the only approved NOAC to act by direct thrombin inhibition. They focus on molecule discovery, animal models of thrombosis, clinical trials and post-launch activities in VTE treatment. Expert opinion: Dabigatran demonstrated comparable efficacy to the highly effective warfarin, and a more favourable safety profile in trials of VTE treatment. A favourable anticoagulant safety profile in addition to efficacy is essential for VTE treatment. Availability of the dabigatran-specific reversal agent, idarucizumab, provides a means of rapidly reversing the anticoagulant effect if required. Future investigations into the optimal duration of VTE treatment and an evaluation of the impact of idarucizumab, in real-world studies, could provide valuable information to help optimise treatment for selected patients.Keywords
Funding Information
- Boehringer Ingelheim
This publication has 79 references indexed in Scilit:
- Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatmentVascular Health and Risk Management, 2013
- An evolutionarily conserved program of B-cell development and activation in zebrafishBlood, 2013
- Dabigatran Does Not Prolong the QT Interval with Supratherapeutic Exposure: a Thorough QT Study in Healthy SubjectsClinical Drug Investigation, 2013
- The Discovery of Dabigatran EtexilateFrontiers in Pharmacology, 2013
- Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studiesThrombosis Journal, 2013
- Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteersEuropean Journal of Clinical Pharmacology, 2012
- Antithrombotic Therapy for VTE DiseaseChest, 2012
- Atherosclerosis and Thrombosis: Insights from Large Animal ModelsBioMed Research International, 2011
- Pharmacology and Management of the Vitamin K AntagonistsChest, 2008
- The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjectsBritish Journal of Clinical Pharmacology, 2007